Cargando…

Resveratrol inhibits nonalcoholic fatty liver disease in rats

BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bujanda, Luis, Hijona, Elizabeth, Larzabal, Mikel, Beraza, Marta, Aldazabal, Pablo, García-Urkia, Nerea, Sarasqueta, Cristina, Cosme, Angel, Irastorza, Belen, González, Alberto, Arenas, Juan I
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547101/ https://www.ncbi.nlm.nih.gov/pubmed/18782455 http://dx.doi.org/10.1186/1471-230X-8-40

Ejemplares similares

Effect of resveratrol on alcohol-induced mortality and liver lesions in mice
por: Bujanda, Luis, et al.
Publicado: (2006)

Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
por: Hijona, Elizabeth, et al.
Publicado: (2012)

Effect of pravastatin on the survival of patients with advanced gastric cancer
por: Bujanda, Luis, et al.
Publicado: (2015)

Inflammatory Mediators of Hepatic Steatosis
por: Hijona, Elizabeth, et al.
Publicado: (2010)

Evaluation of Alpha 1-Antitrypsin and the Levels of mRNA Expression of Matrix Metalloproteinase 7, Urokinase Type Plasminogen Activator Receptor and COX-2 for the Diagnosis of Colorectal Cancer
por: Bujanda, Luis, et al.
Publicado: (2013)

Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats
por: Aguirre, Leixuri, et al.
Publicado: (2019)

Development of resveratrol with thiolated alginate as a supplement to prevent nonalcoholic fatty liver disease (NAFLD)
por: Ke, Yong-Chen, et al.
Publicado: (2022)

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
por: He, Xuan, et al.
Publicado: (2023)

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
por: Mowry, Christopher J., et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Nutritional Genomics in Nonalcoholic Fatty Liver Disease
por: Vasconcellos, Carolina, et al.
Publicado: (2023)

Synergistic delivery of resveratrol and ultrasmall copper-based nanoparticles by aptamer-functionalized ultrasound nanobubbles for the treatment of nonalcoholic fatty liver disease
por: Guo, Xinmin, et al.
Publicado: (2022)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system
por: Tiao, Mao-Meng, et al.
Publicado: (2018)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Probiotics and Nonalcoholic Fatty liver Disease
por: Eslamparast, Tannaz, et al.
Publicado: (2013)

Sirtuins and nonalcoholic fatty liver disease
por: Nassir, Fatiha, et al.
Publicado: (2016)

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2017)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Role of bioactive fatty acids in nonalcoholic fatty liver disease
por: Juárez-Hernández, Eva, et al.
Publicado: (2016)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2019)

Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease
por: Obika, Mikako, et al.
Publicado: (2012)

Nuclear Receptors in Nonalcoholic Fatty Liver Disease
por: López-Velázquez, Jorge A., et al.
Publicado: (2012)

Lipoprotein metabolism in nonalcoholic fatty liver disease
por: Jiang, Zhenghui Gordon, et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
por: Kikuchi, Luciana, et al.
Publicado: (2014)

Role of Mitochondria in Nonalcoholic Fatty Liver Disease
por: Nassir, Fatiha, et al.
Publicado: (2014)

Update on Berberine in Nonalcoholic Fatty Liver Disease
por: Liu, Yang, et al.
Publicado: (2013)

Nonalcoholic fatty liver disease: new treatments
por: Hardy, Timothy, et al.
Publicado: (2015)

MicroRNAs in Nonalcoholic Fatty Liver Disease
por: Baffy, György
Publicado: (2015)

Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease
por: Chen, Guanliang, et al.
Publicado: (2016)

Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Inayat, Faisal, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease in South Asia
por: Pati, Girish K, et al.
Publicado: (2016)

Mediterranean diet and nonalcoholic fatty liver disease
por: Anania, Caterina, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease: Evolving paradigms
por: Lonardo, Amedeo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f9b0u61qvs8jho6cpfreosou2o